Key result
Benidipine linked to ~72% lower MACE risk vs nifedipine in hypertensive CAD patients.
Why the study?
Although calcium channel blockers can prevent cardiovascular events in patients with coronary artery disease, their comparative impact on prognosis among patients with and without chronic kidney disease required investigation.
Does benidipine or amlodipine reduce MACE compared to nifedipine in hypertensive patients with CAD?
Observational (n=142)
No
Does benidipine or amlodipine reduce MACE compared to nifedipine in hypertensive patients with CAD?
Effect estimate: HR 0.28 (95% CI 0.08-1.00)
Absolute Event Rate: 4.5% vs 22.6%
p-value: p=0.049
In hypertensive patients with CAD, long-acting calcium channel blockers benidipine and amlodipine significantly reduced the frequency of MACE compared to nifedipine, particularly in those with concurrent chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
May favor benidipine over nifedipine in hypertensive CAD; extends CCB evidence but requires RCT confirmation.
山岸 et al. (2010) conducted an observational in Coronary artery disease and hypertension (n=142). Benidipine vs. Nifedipine was evaluated on Major adverse cardiovascular events (MACE) (HR 0.28, 95% CI 0.08-1.00, p=0.049). Benidipine significantly reduced the risk of major adverse cardiovascular events (HR 0.28) compared to nifedipine in hypertensive patients with coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: